Evidence map›Paper›PMID 30015556›Full record

ArticleJournal of feline medicine and surgery2019

Investigation of hallmarks of carbonyl stress and formation of end products in feline chronic kidney disease as markers of uraemic toxins.

Emanuela Valle, Liviana Prola, Diana Vergnano, Roberta Borghi, Fiammetta Monacelli, Nicola Traverso, Natascia Bruni, Andrea Bovero, Achille Schiavone, Joana Nery and 2 more

Open access · greenAbstract read
In one paragraph

Article in Journal of feline medicine and surgery, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.5field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Serum IL-6 as a marker of disease progression in interstitial nephritis.American journal of translational research · 2022
    Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Emanuela Valle1 Department of Veterinary Sciences, University of Turin, Grugliasco, Italy.
Liviana Prola1 Department of Veterinary Sciences, University of Turin, Grugliasco, Italy.
Diana Vergnano1 Department of Veterinary Sciences, University of Turin, Grugliasco, Italy.ORCID 0000-0001-7412-1014
Roberta Borghi2 Department of Internal Medicine and Medical Specialties, Genoa, Italy.
Fiammetta Monacelli2 Department of Internal Medicine and Medical Specialties, Genoa, Italy.
Nicola Traverso2 Department of Internal Medicine and Medical Specialties, Genoa, Italy.
Natascia Bruni3 Istituto Farmaceutico Candioli S.p.A., Beinasco, Italy.
Andrea Bovero4 Veterinary Clinic Valsusa, Avigliana, Italy.
Achille Schiavone1 Department of Veterinary Sciences, University of Turin, Grugliasco, Italy.
Joana Nery1 Department of Veterinary Sciences, University of Turin, Grugliasco, Italy.
Domenico Bergero1 Department of Veterinary Sciences, University of Turin, Grugliasco, Italy.
Patrizio Odetti2 Department of Internal Medicine and Medical Specialties, Genoa, Italy.
University of Turin · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesCats are commonly affected by chronic kidney disease (CKD). Many reactive carbonyl intermediates and end products originating from the oxidative stress pathways are recognised as uraemic toxins and may play a role in CKD progression. The aim of the present study is to confirm whether carbonyl end-product formation is higher in cats affected by CKD and to assess whether an angiotensin-converting enzyme inhibitor (ACEi) might affect these hallmarks.

methodsTwenty-two cats were divided into three groups: a control group (CG), cats with CKD and cats with CKD treated with an ACEi. Serum levels of pentosidine, carboxymethyllysine, advanced oxidation protein products, malondialdehyde, methylglyoxal and hexanoyl-lysine were measured. In addition, biochemical parameters and systolic blood pressure were evaluated. After checking for normality, comparisons between groups were performed followed by multiple comparison tests. P values ⩽0.05 were considered significant. Correlations between concentrations of the considered biomarkers and of the other metabolic parameters were investigated.

resultsAdvanced oxidation protein products, malondialdehyde and hexanoyl-lysine concentrations were significantly higher in CKD and ACEi-treated groups compared with the CG ( P <0.05). Carboxymethyllysine increased in the ACEi-treated group when compared with the CG, whereas intermediate values of these biomarkers were found in the CKD group ( P <0.05). The ACEi-treated group showed the highest values of carboxymethyllysine, advanced oxidation protein products and hexanoyl-lysine. By contrast, the CKD group had the highest concentration of malondialdehyde. No statistically significant difference was found in the levels of pentosidine or methylglyoxal. End products correlated with creatinine and urea and with each other. CONCLUSIONS AND RELEVANCE: Significantly high concentrations of both intermediate and end products of carbonyl/oxidative stress were detected in CKD cats. This is the first study to have concurrently taken into account several uraemic toxins and biochemical parameters in cats affected by CKD.

Indexed as

Renal Insufficiency, ChronicAdvanced Oxidation Protein ProductsAngiotensin-Converting Enzyme InhibitorsAnimalsArginineBiomarkersCatsLysineOxidative StressUreaAdvanced Oxidation Protein ProductsAngiotensin-Converting Enzyme InhibitorsArginineBiomarkersLysineN(6)-carboxymethyllysinepentosidineUreaACE inhibitorcarbonyl stressChronic kidney diseaseoxidative stressuraemic toxin

Identifiers

PMID30015556
PMCPMC10814538
OpenAlexW2883873950

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.